Cowen Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
July 24, 2015 9:14 AM EDTCantor Fitzgerald downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Buy to Hold with a price target of $2.00 (from $4.00).
Analyst Mara Goldstein commented, "We are downgrading shares of Sunesis to HOLD from BUY based on the disappointing FDA guidance that will require... More
Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Sell, $1 PT
July 24, 2015 7:32 AM EDTRoth Capital downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Buy to Sell with a price target of $1.00 (from $5.50).
Analyst Joseph Pantginis commented, "Sunesis provided the much anticipated regulatory updates from both the FDA and EMA with mixed results, though we believe the... More
Sunesis Pharmaceuticals (SNSS) Issues Update on Meetings with EMA, FDA Over Vosaroxin in AML
July 23, 2015 4:22 PM EDTSunesis Pharmaceuticals (NASDAQ: SNSS) announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid leukemia (AML) in Europe and the United States.
With respect to Europe, the company recently met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guide the company through the Marketing Authorization Application (MAA) process. Based on these substantive discussions, the company was encouraged to proceed with an MAA... More
